Clinical trial · Observational
Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4
Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4: a Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In patients with colonic adenocarcinoma stage 4 which are potentially resectable metastases (lung and liver metastases), treatment with chemotherapy is necessary but not end in success in 10% of cases. The development of techniques for administering personalized treatment becomes necessary for these patients. Thus, in vitro tests on cells from tumors of these patients and evaluating the effect of chemotherapy on these could be made for each patient. In France, the company develops Oncomedics these tests. This is a pilot study that will make a first evaluation under actual conditions of chimio-oncogramme.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chimio-oncogramme | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Oncogramme
- description
- Taking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
- interventionNames
- Other: Chimio-oncogramme
Primary outcomes (1)
- measure
- In vitro analysis of chemotherapy responses
- timeFrame
- 7 days
- description
- Evaluate the predictive value of chemo-oncogramme on the patient's response to the same (s) chemotherapy (s)
Secondary outcomes (1)
- measure
- quality of life
- timeFrame
- 7 days
- description
- Evaluate the predictive value of chemo-oncogramme on chemical toxicity and quality of life of patients.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patient with adenocarcinoma of the colon diagnosed at stage 4 receiving standard therapy * targets must be measurable tumor lesions (RECIST) * patient has not expressed opposition to the use of their residual tumor Exclusion Criteria: * Against-formal indication to an indispensable para-clinical examination of the patient monitoring * Use of chemotherapy, hormone therapy or concomitant radiotherapy * Cons-indication for chemotherapy * Are pregnant, nursing or lack of contraception for women of childbearing age.
References
Publications (1)
- DERIVEDBounaix Morand du Puch C, Nouaille M, Giraud S, Labrunie A, Luce S, Preux PM, Labrousse F, Gainant A, Tubiana-Mathieu N, Le Brun-Ly V, Valleix D, Guillaudeau A, Mesturoux L, Coulibaly B, Lautrette C, Mathonnet M. Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer. J Transl Med. 2016 Jan 12;14:10. doi: 10.1186/s12967-016-0765-4. PMID 26791256